Drug Database
AL

albumin (albumin, Qiombiotec)

✓ Approved

Quimbiotec · Cell-based Therapies · Cell-based Therapies

What is albumin?

albumin is a cell-based therapies developed by Quimbiotec. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand Namesalbumin, Qiombiotec
CompanyQuimbiotec
Drug ClassCell-based Therapies
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Quimbiotec

Therapeutic Indications

albumin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersHypoalbuminaemia✓ Approved

Related Research Articles

PubMedFrontiers in cellular and infection microbiology2026-07-25

Admission albumin and C-reactive protein-to-lymphocyte ratio are associated with MRI-defined abscess in children with acute hematogenous osteomyelitis: a two-center retrospective study.

Zhao Chaochen C, Guan Zhiye Z, Ke Chenghui C, Wang Xiaodong X et al.

Intramedullary and subperiosteal abscesses are clinically relevant MRI-defined phenotypes in children with acute hematogenous osteomyelitis (AHO). This study examined admission-phase markers associated with MRI-defined abscess and constructed an exploratory pre-MRI risk-stratification model. This two-center retrospective cohort study included 105 children with AHO who underwent MRI within 72 hours of admission. Clinical variables and admission laboratory indices were analyzed using univariable analyses and multivariable Firth penalized logistic regression. Model performance was assessed using receiver operating characteristic analysis, calibration assessment, decision curve analysis, stratified cross-validation, and bootstrap optimism correction. MRI-defined abscess was present in 45 children (42.9%). Lower albumin and higher CRP-to-lymphocyte ratio were independently associated with MRI-defined abscess, whereas fever at admission was retained as a prespecified clinically relevant covariate rather than interpreted as an independent predictor. The final model showed modest discrimination (apparent AUC, 0.711; bootstrap 95% CI, 0.624-0.826; optimism-corrected AUC, 0.689). At the exploratory Youden-derived cutoff of 0.456, sensitivity was 0.600 and specificity was 0.767. Admission albumin and CRP-to-lymphocyte ratio are readily available markers associated with MRI-defined abscess and may support early identification of children who warrant heightened attention to timely MRI and multidisciplinary review. The model requires external validation and should complement, not replace or delay, clinical assessment, MRI, and surgical evaluation.

PMID 42499549
Read full article →
PubMedClinical and translational science2026-07-25

Population Pharmacokinetics of Rituximab in Treatment-Naïve Chinese Patients With Diffuse Large B-cell Lymphoma During Induction Therapy: Clinical Implications.

Zhou Wan-Yi WY, Ling Jing J, Guan Meng-Meng MM, Qu Ying Y et al.

This study aimed to establish and validate a population pharmacokinetic model for rituximab during induction therapy in treatment-naive patients with diffuse large B-cell lymphoma, identify covariates affecting key pharmacokinetic parameters, and predict exposure. This retrospective study included newly diagnosed patients receiving rituximab-containing induction regimens. Blood samples were collected before the next dose and after completion of the current dose across different chemotherapy cycles during the induction therapy; plasma concentrations were measured by chemiluminescent immunoassay. A nonlinear mixed-effects model was developed and externally validated. Individual parameters were obtained using empirical Bayesian methods, and first-cycle trough concentrations were predicted. For model building, 45 patients and 115 samples were included; external validation used 12 patients and 28 samples. Rituximab pharmacokinetics were described by a two-compartment model. Representative estimates were: clearance 0.0181 L/h, central volume 8.12 L, intercompartmental clearance 0.0213 L/h, peripheral volume 29.2 L. Albumin-globulin ratio was the final covariate and significantly affected clearance. Validation indicated good stability and predictive performance. Predicted first-cycle trough concentrations were below the reference efficacy threshold, and lower troughs were associated with smaller albumin-globulin ratios. This model quantified the effect of albumin-globulin ratio on clearance and suggests a risk of insufficient rituximab exposure during induction therapy, supporting future individualized dosing and therapeutic drug monitoring.

PMID 42499290
Read full article →
PubMedMedicine2026-07-25

C-reactive protein/albumin ratio as a potential inflammatory marker for predicting clinical outcomes in patients with moderate to severe ulcerative colitis: A retrospective study.

Morshed Ali A, Alborzi Avanaki Foroogh F, Miroliaee Arash A, Azarboo Alireza A et al.

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that may range from mild to severe; therefore, management and prognosis remain quite challenging. Traditional assessment methods include endoscopy, which is invasive and expensive. This current study investigates the C-reactive protein/albumin ratio and other inflammatory biomarkers as potential noninvasive biomarkers for the prediction of clinical outcomes in ulcerative colitis patients. We conducted a retrospective study of 106 patients with moderate to severe UC between April 2017 and August 2023. We analyzed CAR alongside other inflammatory ratios, including platelet/lymphocyte ratio and neutrophil/lymphocyte ratio, to assess their association with clinical outcomes and predictive performance including anti-TNF therapy need, colectomy, and hospital length of stay. Several inflammatory markers were significantly associated with clinical outcomes. A higher polymorphonuclear leukocyte was associated with an increased need for anti-TNF therapy (odds ratio [OR] = 1.00, 95% confidence interval [CI]: 1.00-1.01, P = .038). Elevated C-reactive protein levels were linked to a higher likelihood of anti-TNF therapy (OR = 1.02, 95% CI: 1.00-1.03, P = .008) and colectomy (OR = 1.02, 95% CI: 1.01-1.04, P = .005). CAR also significantly predicted these outcomes, with an OR of 1.04 (95% CI: 1.01-1.08, P = .007) for anti-TNF therapy and 1.05 (95% CI: 1.01-1.09, P = .011) for colectomy. Additionally, CAR was positively associated with prolonged hospital stay (β = 0.07, 95% CI: 0.01-0.13, P = .020), as was C-reactive protein (β = 0.02, 95% CI: 0.00-0.04, P = .041) and lower hemoglobin levels (β = -0.59, 95% CI: -1.00 to -0.18, P = .005). The C-reactive protein/albumin ratio may serve as a useful complementary biomarker associated with adverse clinical outcomes in patients with moderate to severe UC, although its predictive performance was modest. Other markers, such as the erythrocyte sedimentation rate/albumin ratio, also correlated with extended hospitalization. These findings suggest CAR may serve as a complementary biomarker for monitoring disease progression and guiding treatment decisions. Further multicenter, prospective studies are needed to confirm these results.

PMID 42499090
Read full article →
PubMedEnvironmental toxicology and pharmacology2026-07-25

Perfluorohexane sulfonate (PFHxS) modulates conformational transitions, ligand-binding functions and aggregation of human serum albumin.

Suramya Suramya S, Muthu Shivani A SA, Chauhan Chanchal C, Qureshi Afnaan A et al.

Perfluorohexane sulfonate (PFHxS), a persistent short-chain member of perfluoroalkyl substances (PFAS) family, exhibits a long biological half-life and widespread human exposure, raising toxicological concerns. Human serum albumin (HSA), the most abundant plasma protein, regulates transport of xenobiotics, including PFAS, yet the effects of PFHxS binding remain unclear. This study examined PFHxS-HSA interactions across pH-dependent isomeric states using an integrated approach. PFHxS preferentially bound to hydrophobic cavities, particularly Sudlow's site I, via hydrophobic and electrostatic interactions, supported by docking, molecular dynamics, and molecular mechanics/Poisson-Boltzmann surface area (MM-PBSA) analyses. Spectroscopic data revealed isomer-specific conformational changes, reduced α-helical content, and stabilization of partially unfolded intermediates. At physiological pH, PFHxS displaced diazepam, indicating impaired drug-binding capacity. PFHxS also remodeled the aggregation pathway of HSA, promoting smaller oligomeric species rather than amyloid-like aggregates. Conclusively, PFHxS acts as an active modulator of HSA structure and function, influencing ligand transport, bioavailability, and pharmacokinetics, underscoring potential risks of persistent environmental PFAS exposure to human health.

PMID 42498051
Read full article →
PubMedAnnals of medicine2026-07-25

A nonlinear association between platelet-to-albumin ratio and one-year all-cause mortality in acute coronary syndrome patients.

Li Jiaxin J, Chen Lujun L, Kang Yuan Y, Li Zhizhen Z et al.

The platelet-to-albumin ratio (PAR) has shown to be linked with cardiovascular disorders. However, the specific association between the admission PAR and one-year outcomes in patients with acute coronary syndrome (ACS) remains to be fully characterized. This study investigated the linkage between PAR levels and the occurrence of one-year all-cause mortality and major adverse cardiovascular and cerebrovascular events (MACCEs) in the ACS population. This retrospective cohort study enrolled patients diagnosed with ACS between January 2022 and December 2023. The primary endpoint was one-year all-cause mortality, and the secondary endpoint was MACCE, defined as a composite of all-cause mortality, non-fatal myocardial infarction, ischemic stroke, heart failure rehospitalization, target vessel revascularization or in-stent thrombosis, and malignant arrhythmia. To evaluate the relationship between PAR and these clinical events, we employed multivariate Cox proportional hazards models, restricted cubic splines (RCSs) and two-piecewise linear regression to identify potential non-linear associations and specific inflection points. A total of 1326 participants (median age: 67 years) were followed for one year, during which 137 (10.3%) deaths and 280 (21.1%) MACCE events occurred. The one-year all-cause mortality rates across the PAR quartiles (Q1-Q4) were 11.6%, 6.1%, 7.0% and 16.7%, respectively, with a similar trend observed for MACCE (22.1%, 15.2%, 18.7% and 28.5%). RCS analysis revealed significant nonlinear associations between the PAR and both clinical endpoints (all p for nonlinear < 0.05). Two-piecewise linear regression analysis identified specific inflection points at 5.28 (95% confidence interval [CI]: 4.86-9.86) for one-year all-cause mortality and 5.29 (95% CI: 4.37-6.58) for MACCE. The PAR demonstrates a significant nonlinear relationship with one-year all-cause mortality and MACCE in patients with ACS.

PMID 42499241
Read full article →
PubMedInternational urology and nephrology2026-07-25

Efficacy of telitacicept on renal outcomes in patients with biopsy-proven lupus nephritis: a 12-month follow-up pilot study.

Zhang Tingmin T, Wang Zihan Z, Jiang Jielong J, Wang Lihua L et al.

To investigate the efficacy of telitacicept in patients with biopsy-proven lupus nephritis. Twenty-one patients diagnosed with lupus nephritis by taking the renal biopsy were enrolled in this study and received telitacicept treatment for at least 6 months. The laboratory test and renal remission rate were assessed during the follow-up period. All patients were followed for at least 12 months. At the 12-month follow-up, patients with Class II, III, or V LN all had achieved complete or at least partial remission, whereas some patients with Class III + V, IV, or IV + V LN had not achieved remission. However, with extended follow-up (median of 24 months), all patients ultimately achieved complete or partial remission by the end of the study. Significant improvements were observed at 3 months, including a decrease in the urinary protein to creatinine ratio (UPCR) and increases in serum albumin (ALB) and hemoglobin (Hb) levels. C3, C4 complement concentrations, and platelet (PLT) were markedly elevated at 1 month, while immunoglobulins (IgG, IgA, and IgM) decreased significantly and remained at low levels over the following 12 months. No severe adverse events were reported during the observation period. Compared with the noninitial-treatment group, patients initially treated with telitacicept had significantly lower baseline albumin, C3, and C4 levels, but subsequent follow-up revealed no statistically significant differences between the groups. Telitacicept is a promising treatment option for patients with LN. The study demonstrated favorable efficacy and safety in LN patients, regardless of whether they were undergoing initial therapy, had failed previous treatments, or had experienced disease relapse. Further randomized controlled trials are warranted to confirm this conclusion.

PMID 42498888
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about albumin